Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices 77875 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; HIV 

COMORBIDITIES AND RESERVOIRS. 

Date: November 8, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Maria E. Davila-Bloom, 

Ph.D., Scientific Review Officer, National 

Institute of Diabetes and Digestive and 

Kidney Diseases, National Institutes of 

Health, 6707 Democracy Boulevard, Rm. 

7017, Bethesda, MD 20892–5452, (301) 594– 

7637, davila-bloomm@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 18, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–21736 Filed 9–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; Review of Support for Research 

Excellence (SuRE) Program and Support for 

Research Excellence—First Independent 

Research (SuRE-First) Award (R16). 

Date: October 31–November 1, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute of General Medical 

Sciences, Natcher Building, 45 Center Drive, 

Bethesda, Maryland 20892 (Virtual Meeting). 

Contact Person: John J. Laffan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, 45 Center Drive, Room 

3AN18J, Bethesda, Maryland 20892, 301– 

594–2773, laffanjo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: September 18, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–21740 Filed 9–23–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Haiqing Li at 240–627–3708, or lihai@

mail.nih.gov. Licensing information 

may be obtained by communicating 

with the Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Rockville, 

MD 20852: tel. 301–496–2644. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished information related to the 

invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Monoclonal Antibodies That Bind to 

the Underside of Influenza Viral 

Neuraminidase 

Description of Technology 

Current influenza vaccines mainly 

induce antibodies against the surface 

glycoprotein hemagglutinin (HA) that 

block viral attachment to its host 

receptors and viral membrane fusion to 

the host cell. The immunodominant 

head region of HA undergoes antigenic 

drift and antibodies directed to the head 

confer little cross-protections between 

strains or subtypes. 

Researchers at the Vaccine Research 

Center of the National Institute of 

Allergy and Infectious Diseases have 

identified human monoclonal 

antibodies that each bind distinct 

epitopes on the less abundant yet 

critical viral surface glycoprotein 

neuraminidase (NA). These antibodies, 

isolated from convalescent individuals 

with confirmed influenza A H3N2 

infection, inhibit viral propagation of a 

wide range of human H3N2, swineorigin variant H3N2, and H2N2 viruses 

and confer pre-exposure and postexposure protection from lethal H3N2 

infection in mice. Cryo-electron 

microscopy revealed that two of these 

antibodies bind non-overlapping 

epitopes covering the underside of the 

NA head, thus defining a potential 

vaccine target. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications 

• Prevention or treatment of influenza 

infection 

• Testing influenza antigens 

Competitive Advantages 

• Improved breadth of protection 

relative to influenza HA-targeting 

antibodies 

Development Stage: Preclinical. 

Inventors: Masaru Kanekiyo (NIAID), 

Sarah Andrews (NIAID), Julia 

Lederhofer (NIAID), Yaroslav Tsybovsky 

(Leidos Biomedical Research). 


lotter on DSK11XQN23PROD with NOTICES1